Davide Festi, Sandra Sottili, Antonio Colecchia, Adolfo Attili, Giuseppe Mazzella, Enrico Roda, Ferdinando Romano, MICOL Research Group – 30 December 2003 – Despite the many efforts to delineate the clinical manifestations of gallbladder disease, the precise symptom complex associated with gallstones is still a matter of debate, and even the existence of gallstone‐specific symptoms has been questioned. We carried out a large population‐based cross‐sectional study (MICOL) to identify symptoms significantly related to gallstones.

Jeffrey A. Rudolph, William F. Balistreri – 30 December 2003

Ahmed M. Elsharkawy, Matthew C. Wright, Ron T. Hay, Michael J. Arthur, Timothy Hughes, Matthias J. Bahr, Klaus Degitz, Derek A. Mann – 30 December 2003 – Rat hepatic stellate cells (HSC) cultured in serum‐containing medium underwent a rapid (3‐hour) classical induction of p50:p65 and p65:p65 nuclear factor‐κB (NF‐κB) dimers. Subsequent culturing was associated with prolonged expression of active p50:p65 and persistent induction of a high‐mobility NF‐κB DNA binding complex consisting of potentially novel Rel‐like protein(s).

Antonio Craxì, Guglielmo Mariani – 30 December 2003

George V. Papatheodoridis, John Goulis, Gioacchino Leandro, David Patch, Andrew K. Burroughs – 30 December 2003 – Endoscopic treatment (ET) is frequently used to prevent variceal rebleeding but this still occurs in about 50% of patients. Recently, transjugular intrahepatic portosystemic shunt (TIPS) has been compared with ET in several trials. Using a meta‐analysis, we evaluated randomized trials comparing TIPS to ET assessing prevention of rebleeding, survival, and the effects on resource use and the quality of patients' lives.

Rong‐Nan Chien, Yun‐Fan Liaw, Mark Atkins – 30 December 2003 – In the reported Asian lamivudine trial, the rate of hepatitis B e antigen (HBeAg) seroconversion, defined as HBeAg/hepatitis B virus (HBV) DNA seroclearance and development of anti‐HBe, during 52 weeks of treatment was only 13% to 16%. To evaluate whether any factors influenced HBeAg seroconversion, data from 345 patients in that trial were reanalyzed to correlate HBeAg seroconversion with variables including treatment, age, gender, body build, histology, baseline HBV‐DNA levels, and alanine transaminase (ALT) levels.

Thomas L. Freeman, Hao Q. Ngo, Mark E. Mailliard – 30 December 2003 – System A, the sodium‐dependent neutral amino acid transport activity, has a 3‐fold increase in its initial uptake velocity into hepatocytes following partial hepatectomy (PH) in the rat. The purpose of this study was to examine the effect of inhibition of System A–mediated amino acid transport on hepatocyte proliferation and liver regeneration. We describe thein vivocompetitive inhibition of System A activity following PH by the nonmetabolizable, System A–specific substrate, α‐(methylamino)isobutyric acid (MeAIB).

Fritz von Weizsäcker, Josef Köck, Stefan Wieland, Wolf‐Bernhard Offensperger, Hubert E. Blum – 30 December 2003 – Dominant negative (DN) mutants of the hepadnaviral core protein are potent inhibitors of viral replication. We have previously shown that fusion of sequences derived from the duck hepatitis B virus (DHBV) polymerase (Pol), DHBV small surface protein (S), bacterial β‐galactosidase (lacZ), or green fluorescent protein (GFP) to the carboxy terminus of the DHBV core protein yields DN mutants that inhibit viral replication at the posttranslational level.

Gregory T. Everson, Donald M. Jensen, John R. Craig, Dirk J. van Leeuwen, Vincent G. Bain, Murray N. Ehrinpreis, Donald Albert, Tenshang Joh, Karsten Witt – 30 December 2003 – Chronic hepatitis C patients (472 patients) were treated with consensus interferon (CIFN) or interferon (IFN) alfa‐2b for 6 months in a large multicenter trial. Efficacy was assessed by clearance of hepatitis C virus (HCV) RNA using reverse transcription polymerase chain reaction (RT‐PCR) (<100 copies/mL), normalization of serum alanine aminotransferase (ALT), and histological improvement.

Alessandro Tagger, Francesco Donato, Maria Lisa Ribero, Giorgio Binelli, Umberto Gelatti, Giuseppe Portera, Alberto Albertini, Michele Fasola, Roberta Chiesa, Giuseppe Nardi – 30 December 2003 – We performed a case‐control study to evaluate the association of a new human DNA virus named TT virus (TTV) with hepatocellular carcinoma (HCC). We recruited 174 subjects hospitalized for HCC (84% males; mean age: 64 years) and 118 patients hospitalized for non‐liver diseases in Brescia, northern Italy, as controls (94% males; mean age: 66 years).